K. Bartelheim

1.1k total citations
19 papers, 353 citations indexed

About

K. Bartelheim is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Gastroenterology. According to data from OpenAlex, K. Bartelheim has authored 19 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Pathology and Forensic Medicine and 5 papers in Gastroenterology. Recurrent topics in K. Bartelheim's work include Chromatin Remodeling and Cancer (10 papers), Cancer Mechanisms and Therapy (7 papers) and Gastrointestinal Tumor Research and Treatment (5 papers). K. Bartelheim is often cited by papers focused on Chromatin Remodeling and Cancer (10 papers), Cancer Mechanisms and Therapy (7 papers) and Gastrointestinal Tumor Research and Treatment (5 papers). K. Bartelheim collaborates with scholars based in Germany, United States and Italy. K. Bartelheim's co-authors include Michael C. Frühwald, Martin Hasselblatt, Reinhard Schneppenheim, Uwe Kordes, Werner Paulus, Reiner Siebert, Astrid Jeibmann, Florian Oyen, Julia Richter and Inga Nagel and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and International Journal of Cancer.

In The Last Decade

K. Bartelheim

17 papers receiving 344 citations

Peers

Countries citing papers authored by K. Bartelheim

Since Specialization

Citations

This map shows the geographic impact of K. Bartelheim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Bartelheim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Bartelheim more than expected).

Fields of papers citing papers by K. Bartelheim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Bartelheim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Bartelheim. The network helps show where K. Bartelheim may publish in the future.

Co-authorship network of co-authors of K. Bartelheim

This figure shows the co-authorship network connecting the top 25 collaborators of K. Bartelheim. A scholar is included among the top collaborators of K. Bartelheim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Bartelheim. K. Bartelheim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Detection of SMARCB1 loss in ascites cells in the diagnosis of an abdominal rhabdoid tumor 2015 ·Pediatric Blood & Cancer ·Kornelius Kerl, Florian Oyen, Ivo Leuschner, Reinhard Schneppenheim, Inga Nagel, Reiner Siebert, Andreas H. Groll, Wolfgang Hartmann, Peter Barth, K. Bartelheim, (unknown), Eva Wardelmann, Michael C. Frühwald	1
2	Clinical and genetic features of rhabdoid tumors of the heart registered with the European Rhabdoid Registry (EU-RHAB) 2014 ·Cancer Genetics ·K. Bartelheim, David Sumerauer, Uta Behrends, Daniela Kodetová, Filip Kučera, Ivo Leuschner, (unknown), Florian Oyen, Christian Rübe, Reiner Siebert, Reinhard Schneppenheim, Angela Seeringer, (unknown), Michael C. Frühwald	7
3	Identification of genes involved in the biology of atypical teratoid/rhabdoid tumours using Drosophila melanogaster 2014 ·Nature Communications ·Astrid Jeibmann, (unknown), (unknown), Marcel Kool, Björn Koos, (unknown), Stefanie Albrecht, K. Bartelheim, Michael C. Frühwald, Stefan M. Pfister, Werner Paulus, Martin Hasselblatt	25
4	Synchronous congenital malignant rhabdoid tumor of the orbit and atypical teratoid/rhabdoid tumor—feasibility and efficacy of multimodal therapy in a long-term survivor 2014 ·Cancer Genetics ·Angela Seeringer, Harald Reinhard, Martin Hasselblatt, Reinhard Schneppenheim, Reiner Siebert, K. Bartelheim, Ivo Leuschner, Michael C. Frühwald	17
5	Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1 2014 ·International Journal of Cancer ·Kornelius Kerl, Natalia Moreno, Till Holsten, Julia Ahlfeld, (unknown), Marc Hotfilder, Marcel Kool, K. Bartelheim, Sabine Schleicher, Rupert Handgretinger, Ulrich Schüller, Michael Meisterernst, Michael C. Frühwald	37
6	High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): a report from the European Rhabdoid Registry (EU-RHAB) 2014 ·Bone Marrow Transplantation ·Martin Benesch, K. Bartelheim, Gudrun Fleischhack, Bernd Gruhn, Paul G. Schlegel, Olaf Witt, (unknown), Holger Hauch, Christian Urban, Franz Quehenberger, Maura Massimino, Torsten Pietsch, Martin Hasselblatt, Felice Giangaspero, Uwe Kordes, Reinhard Schneppenheim, Péter Hauser, T. Klingebiel, Michael C. Frühwald	55
7	Feasibility of Intensive Multimodal Therapy in Infants Affected by Rhabdoid Tumors – Experience of the EU-RHAB registry 2014 ·Klinische Pädiatrie ·Angela Seeringer, K. Bartelheim, Kornelius Kerl, Martin Hasselblatt, Ivo Leuschner, Stefan Rutkowski, Beate Timmermann, Rolf‐Dieter Kortmann, Ewa Kościelniak, Reinhard Schneppenheim, Monika Warmuth‐Metz, Joachim Gerß, Reiner Siebert, Norbert Graf, Joachim Boos, Michael C. Frühwald	26
8	Clinical Characteristics and Outcome of Children with Extracranial, Extrarenal Rhabdoid Tumors Registered to the European Rhabdoid Registry 2007–2013 2014 ·Cancer Genetics ·K. Bartelheim, Angela Seeringer, Ivo Leuschner, (unknown), Beate Timmermann, (unknown), Norbert Graf, E. Koscielniak, (unknown), (unknown), Michael C. Frühwald	0
9	Favorable outcome of patients affected by rhabdoid tumors due to rhabdoid tumor predisposition syndrome (RTPS) 2013 ·Pediatric Blood & Cancer ·Uwe Kordes, K. Bartelheim, Piergiorgio Modena, Maura Massimino, Veronica Biassoni, Harald Reinhard, Martin Hasselblatt, Reinhard Schneppenheim, Michael C. Frühwald	31
10	High‐resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors 2012 ·Genes Chromosomes and Cancer ·Martin Hasselblatt, (unknown), (unknown), (unknown), Astrid Jeibmann, Florian Oyen, Inga Nagel, Julia Richter, K. Bartelheim, Uwe Kordes, Reinhard Schneppenheim, Michael C. Frühwald, Reiner Siebert, Werner Paulus	101
11	Nine Months to Progression Using Fourth-Line Liposomally Encapsulated Paclitaxel against Hepatocellular Carcinoma 2008 ·Chemotherapy ·Maximilian Christopeit, Georg Lenz, Roswitha Forstpointner, K. Bartelheim, Robert Kühnbach, Kurt Naujoks, Andreas Schalhorn	10
12	Intraoperative, adjuvant treatment of gastric cancer with the trifunctional antibody catumaxomab compared to surgery alone: A phase II study 2008 ·Journal of Clinical Oncology ·(unknown), Б. А. Бердов, L Roman, Alexander Luft, Paul D. Lampe, Horst Lindhofer, K. Bartelheim, Alexander Klein, M. M. Heiss	8
13	Intraoperative Immuntherapie mit dem trifunktionalen Antikörper Catumaxomab bei Patienten mit fortgeschrittenem Magen-, Colon- und Pankreaskarzinom: Ergebnisse einer Phase I Pilotstudie Intraoperative Immunotherapy with the trifunctional antibody Catumaxomab in patients with advanced gastric-, colon- and pancreatic carcinoma: a phase I pilot study 2008 ·(unknown), (unknown), Markus Jäger, K. Bartelheim, Horst Lindhofer, M. M. Heiss	4
14	Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: A matched-pair analysis 2006 ·Journal of Clinical Oncology ·(unknown), (unknown), Anwar Tarabichi, (unknown), K. Bartelheim, Horst Lindhofer, Reinhard von Roemeling, M. M. Heiss	9
15	Treatment of peritoneal carcinomatosis due to GI-tract cancer by intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpcAM x anti-CD3): Results of a phase I/II trial 2005 ·Journal of Clinical Oncology ·(unknown), Florian Lordick, (unknown), (unknown), H Menzel, K. Bartelheim, Markus Jaeger, Horst Lindhofer, K.‐W. Jauch, Christian Peschel, M. M. Heiss	9
16	Phase Ib study of the anti-neovascular agent MBT-0206 to evaluate safety and efficacy in patients with metastatic breast cancer 2004 ·Journal of Clinical Oncology ·K. Bartelheim, (unknown), Semiglazov Vf, (unknown), Cortina Kaletta, (unknown), Uwe Michaelis, Kurt Naujoks, (unknown)	2
17	Phase I study of the anti-neovascular agent MBT-0206 to evaluate safety and efficacy in patients with metastatic or advanced unresectable gastrointestinal cancer (GI cancer) 2004 ·Journal of Clinical Oncology ·Karsten Ridwelski, E. Kettner, J. Fahlke, K. Bartelheim, Monika Hitzl, B. Schulze, Robert Koeber, Uwe Michaelis, Kurt Naujoks, Michael Clemens	6
18	Phase Ib study of the anti-neovascular agent MBT-0206 to evaluate safety and efficacy in patients with metastatic breast cancer 2004 ·Journal of Clinical Oncology ·K. Bartelheim, (unknown), Semiglazov Vf, (unknown), (unknown), (unknown), Uwe Michaelis, Kurt Naujoks, Michael Clemens	2
19	Phase I study of the anti-neovascular agent MBT-0206 to evaluate safety and efficacy in patients with metastatic or advanced unresectable gastrointestinal cancer (GI cancer) 2004 ·Journal of Clinical Oncology ·Karsten Ridwelski, E. Kettner, Jörg Fahlke, K. Bartelheim, Monika Hitzl, B. Schulze, Robert Koeber, Uwe Michaelis, Kurt Naujoks, Michael Clemens	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact